| AAV | Adeno-associated virus |
| AAVs | Adeno-associated viruses |
| BBB | Blood–brain barrier |
| CDNA | complementary DNA |
| CNS | Central nervous system |
| CRISPR | Clustered Regularly Interspaced Short Palindromic Repeat |
| CSF | Cerebrospinal fluid |
| DS | Dermatan sulphate |
| ERT | Enzyme replacement therapy |
| FDA | Food and Drug Administration |
| FGF | Fibroblast growth factor |
| GAGs | Glycosaminoglycans |
| GC | Genome copies |
| GvHD | Graft versus host disease |
| gRNA | guide RNA |
| HS | Heparan sulphate |
| HSCT | Hematopoietic stem cell transplantation |
| HR | Homologous recombination |
| iPSCs | induced pluripotent stem cells |
| KSPD | Kyoto Scale of Psychological Development 2001 |
| LSDs | Lysosomal storage disorders |
| MPS I | Mucopolysaccharidosis type I |
| MPS II | Mucopolysaccharidosis type II |
| MPS IIIA | Mucopolysaccharidosis type IIIA |
| NGS | Next Generation Sequencing |
| NHEJ | Nonhomologous end joining |
| PAM | Protospacer adjacent motif |
| SCMAS | Subunit c of mitochondrial ATP synthetase |
| SNV | Single nucleotide variant |
| TALENs | Transcription activator-like effector nucleases |
| TLR4 | Toll-like receptor 4 |
| TNF-α | Tumour necrosis factor α |
| Vg | vector genomes |
| ZFNs | Zinc finger nucleases |